BETA
Investigational catheter-based artificial chord technology for degenerative mitral regurgitation.
CardioMech develops a transcatheter mitral valve repair system intended to replace damaged or elongated chordae with an artificial chord. The design uses a transfemoral, transseptal approach to a beating heart, with the aim of offering a less invasive option for selected patients with degenerative mitral regurgitation.
The company is Norwegian, with development operations described in Fridley, Minnesota. Its website explicitly states that the MVRS is investigational and not for sale in any geography. Early-feasibility research and IDE-related coverage do not constitute commercial marketing approval.
CardioMech announced a $13 million financing in January 2024, reporting $42 million raised to that date. A June 2026 company announcement appointed Ramin Mousavi as board chair and identified Rick Nehm as President and CEO. These dated records supersede older material that combined Nehm’s executive and chair roles.
Investigational device; not available for routine commercial sale. [4][3][5]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [7][8]
Latest recorded source review: 2026-10-20.
No routinely marketed devices established in the reviewed scope.
NCT04820764: registry status active not recruiting in the 2026-09-25 update; 35 participants (estimated). Study completion is estimated for 2031-09; this is not an FDA decision or commercial launch date. [11]
Artificial chord system intended for transfemoral, transseptal mitral valve repair. [4][3][1]
Investigational / in developmentInvestigational only; not commercially available.
June 2026 announcement identifies Mousavi as chair and Rick Nehm as President and CEO. [2]
Company reported $13 million in fresh financing and $42 million cumulative funding at the announcement date. [12]
Accessed 10/29/2026